Jisoo is a global pharmaceutical business development leader with a proven track record. Previously, Jisoo served as Vice President of Business Development and M&A at Covis Pharma. At Covis, Jisoo led global business development and M&A, including transformational buy-side and sell-side M&A, licensing and financings. In less than five years, Jisoo led seven deals worth roughly $2 billion in transaction value, helping expand the organization beyond the U.S. and into more than 50 markets.

Prior to Covis, he was an investment banker in J.P. Morgan’s Global Healthcare team in New York and San Francisco, where he advised companies in the pharmaceuticals, biotech and life sciences industries on M&A, equity and debt financings.

He holds a B.S. in Economics and Statistics from Carnegie Mellon University.

“Melinta is on a mission to make the most meaningful impact for patients with life-threatening illnesses and I’m excited to join the team in the middle of such great momentum. I look forward to working with this truly committed team toward continued growth and expansion to serve patients in need in the U.S. and beyond.”

Kelley Ford is a forward-thinking technical leader in the pharmaceutical industry with a depth of experience across the product lifecycle for analytical, drug substance, and drug product. She’s been an integral part of Melinta’s success since 2016.

Before joining our team, Kelley served as Director of Manufacturing Science & Technology at AbbVie, where she managed the technical operations and third-party manufacturing process for specific product lines.

Previous to that, she held several technical operations positions at AbbVie/Abbott. For nearly 20 years, she was intricately involved in the development, manufacturing, and lifecycle support for several globally marketed pharmaceutical products.

She began her career at Sandoz as a process development chemist.

Kelley holds a B.A. in General Science from the University of Iowa, a B.S. in Chemistry from Elmhurst College, and a Ph.D. in Organic Chemistry from Northwestern University.

Susan is a financial and accounting leader with more than 20 years of diverse experience strengthening corporate financial strategy, efficiencies, and controls. She’s been an integral part of Melinta’s financial and accounting team since 2016.

Before joining Melinta, Susan served as Corporate Controller at Textura, where she oversaw the accounting function and played a lead IPO role with responsibility for centralizing accounting functions post-acquisition.

Before Textura, she held leadership roles at Orbitz Worldwide, Inc., where she directed global technical accounting processes. And before that, Susan managed the SEC reporting and revenue functions at Facet Biotech and PDL BioPharma.

Susan began her career in public accounting at Ernst & Young, where she worked with a diverse client base ranging from large, public international SEC engagements to development-stage enterprises.

She holds a B.S. in Business Commerce from Santa Clara University and is a certified public accountant.

Jennifer is a seasoned life sciences industry executive with demonstrated success in general management, legal, and compliance.

Before Melinta, Jennifer held several leadership roles at The Medicines Company. She led legal and compliance counsel for multiple business units guiding commercial, medical, market access, and regulatory activities in those roles

Before The Medicines Company, Jennifer was an attorney at Porzio, Bromberg & Newman, P.C., a law firm specializing in the life sciences industry. She advised pharmaceutical, medical device, and biotech companies on a variety of legal, regulatory, and compliance issues.

Jennifer holds a B.A. in History, magna cum laude, from New York University and a J.D. from the Rutgers School of Law, where she was managing editor of the Rutgers Law Review.